Viewing Study NCT06608225



Ignite Creation Date: 2024-10-26 @ 3:40 PM
Last Modification Date: 2024-10-26 @ 3:40 PM
Study NCT ID: NCT06608225
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-09-10

Brief Title: Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy
Sponsor: None
Organization: None

Study Overview

Official Title: Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study investigates the prognostic value of dynamic changes in Prostate-Specific Antigen PSA levels found in the peritoneal drainage fluid after radical prostatectomy Prostate cancer is one of the most common cancers in men and radical prostatectomy is a standard treatment While PSA levels in the blood are commonly used as a marker for diagnosis this study focuses on the significance of PSA levels in the prognosis of prostate cancer The findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients
Detailed Description: This study examines the prognostic significance of Prostate-Specific Antigen PSA levels in the peritoneal drainage fluid following radical prostatectomy a common surgical treatment for prostate cancer PSA is widely used as a biomarker for prostate cancer diagnosis treatment response and recurrence monitoring in the blood However this research seeks to explore the prognostic value of PSA in the drainage fluid

The study involves continuous monitoring of PSA levels in the drainage fluid after radical prostatectomy with the hypothesis that dynamic changes in these levels could serve as an early warning system for potential tumor recurrence residual disease or metastasis The research will correlate these fluid PSA levels with patient outcomes recurrence rates and other clinical factors to determine their predictive value

By investigating this novel source of PSA monitoring the study aims to reduce invasive tests enhance post-operative surveillance and improve early detection of disease recurrence for prostate cancer patients This research could contribute to refining post-surgical care protocols offering a new tool for predict long-term outcomes for individuals undergoing radical prostatectomy

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None